Research Frontiers Inc. Files Q3 2024 10-Q

TL;DR

RFG Q3 10-Q filed. Financials updated.

AI Summary

Research Frontiers Inc. filed its 10-Q for the period ending September 30, 2024. The company, based in Woodbury, NY, is a patent owner and lessor. Financial details for the third quarter and year-to-date periods of 2024 and 2023 are presented, including common stock, additional paid-in capital, and retained earnings.

Why It Matters

This filing provides investors with an update on Research Frontiers Inc.'s financial performance and position as of the end of the third quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Latest financial data available)
• 2024-11-07 — Filing Date (When the report was submitted to the SEC)

Key Players & Entities

• Research Frontiers Inc. (company) — Filer of the 10-Q
• Woodbury, NY (location) — Company's business address
• 2024-09-30 (date) — End of the reporting period
• 2024-11-07 (date) — Date of filing

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered Common Stock, $0.0001 Par Value The NASDAQ Stock Market S

Filing Documents

• form10-q.htm (10-Q) — 378KB
• ex31-1.htm (EX-31.1) — 15KB
• ex32-1.htm (EX-32.1) — 8KB
• 0001493152-24-044002.txt ( ) — 2102KB
• refr-20240930.xsd (EX-101.SCH) — 20KB
• refr-20240930_cal.xml (EX-101.CAL) — 31KB
• refr-20240930_def.xml (EX-101.DEF) — 63KB
• refr-20240930_lab.xml (EX-101.LAB) — 168KB
• refr-20240930_pre.xml (EX-101.PRE) — 128KB
• form10-q_htm.xml (XML) — 177KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 15

Controls and Procedures

Item 4. Controls and Procedures 15-16

- OTHER INFORMATION

PART II - OTHER INFORMATION

Exhibits

Item 6. Exhibits 16

SIGNATURES

SIGNATURES 17 2 RESEARCH FRONTIERS INCORPORATED Condensed Consolidated Balance Sheets September 30, 2024 (Unaudited) December 31, 2023 (See Note 1) Assets Current assets: Cash and cash equivalents $ 1,647,987 $ 2,475,958 Royalties receivable, net of reserves of $ 1,253,450 in 2024 and 2023, respectively 1,048,008 1,003,404 Prepaid expenses and other current assets 154,727 96,784 Total current assets 2,850,722 3,576,146 Fixed assets, net 20,758 39,598 Operating lease ROU assets 71,486 178,715 Deposits and other assets 56,066 56,066 Total assets $ 2,999,032 $ 3,850,525 Liabilities and Shareholders' Equity Current liabilities: Current portion of operating lease liability $ 109,968 $ 212,359 Accounts payable 34,306 50,880 Accrued expenses 31,799 14,192 Total current liabilities 176,073 277,431 Operating lease liability, net of current portion - 55,363 Total liabilities 176,073 332,794 Shareholders' equity: Common stock, par value $ 0.0001 per share; authorized 100,000,000 shares, issued and outstanding 33,517,787 in 2024 and 33,509,287 in 2023 3,352 3,351 Additional paid-in capital 127,787,890 127,779,221 Accumulated deficit ( 124,968,283 ) ( 124,264,841 ) Total shareholders' equity 2,822,959 3,517,731 Total liabilities and shareholders' equity $ 2,999,032 $ 3,850,525 See accompanying notes to condensed consolidated financial statements. 3 RESEARCH FRONTIERS INCORPORATED Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 2024 2023 Nine months ended September 30, Three months ended September 30, 2024 2023 2024 2023 Fee income $ 1,157,380 $ 597,362 $ 354,408 $ 164,146 Operating expenses 1,565,152 1,695,129 454,866 542,635 Research and development 409,817 430,150 131,246 135,319 Total expenses 1,974,969 2,125,279 586,112 677,954 Operating loss ( 817,589 ) ( 1,527,917 ) ( 231,704 ) ( 513,808 ) Net investm

View Full Filing

View this 10-Q filing on SEC EDGAR